drugset / Trial / NCT05159219

Colchicine for the Prevention of Vascular Events After an Acute Intracerebral Hemorrhage

NCT05159219

Phase 2 Completed 100 enrolled Population Health Research Institute
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The overall goal is to establish the safety and efficacy of colchicine in ICH patients for the prevention of major cardiovascular events and brain injury. Colchicine for the prevention of vascular events after an acute intracerebral hemorrhage (CoVasc-ICH) is a vanguard pilot trial designed to obtain the factual feasibility prerequisites essential for the planning, design, funding and execution of a subsequent phase III trial.

Timeline

Start
2022-08-04
Primary completion
2024-12-03
Completion
2024-12-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Colchicine Small molecule 0.5 mg Oral